Compaction Behavior of Isomalt after Roll Compaction
AbstractThe suitability of the new isomalt grade galenIQ™ 801 for dry granulation and following tableting is evaluated in this study. Isomalt alone, as well as a blend of equal parts with dibasic calcium phosphate, is roll compacted and tableted. Particle size distribution and flowability of the granules and friability and disintegration time of the tablets are determined. Tensile strength of tablets is related to the specific compaction force during roll compaction and the tableting force. In all cases, the tensile strength increases with raising tableting forces. The specific compaction force has a different influence. For isomalt alone the tensile strength is highest for tablets made from granules prepared at 2 kN/cm and 6 kN/cm and decreases at higher values, i.e., >10 kN/cm. Tensile strength of the blend tablets is almost one third lower compared to the strongest tablets of pure isomalt. Friability of pure isomalt tablets is above the limit. Disintegration time is longest when the tensile strength is at its maximum and decreases with higher porosity and lower tensile strengths. Isomalt proves to be suitable for tableting after roll compaction. Even though the capacity as a binder might not be as high as of other excipients, it is a further alternative for the formulation scientist. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Quodbach, J.; Mosig, J.; Kleinebudde, P. Compaction Behavior of Isomalt after Roll Compaction. Pharmaceutics 2012, 4, 494-500.
Quodbach J, Mosig J, Kleinebudde P. Compaction Behavior of Isomalt after Roll Compaction. Pharmaceutics. 2012; 4(4):494-500.Chicago/Turabian Style
Quodbach, Julian; Mosig, Johanna; Kleinebudde, Peter. 2012. "Compaction Behavior of Isomalt after Roll Compaction." Pharmaceutics 4, no. 4: 494-500.